Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for inflammatory disease, cancer, and diabetes. The company’s products under development include STA-5326, an orally administered, small-molecule inhibitor of interleukin-12 and interleukin-23, which is in Phase 2 clinical development for the treatment of Crohn's disease and psoriasis; STA-4783, a small-molecule anticancer therapeutic, which is in three separate Phase 2 trials for the treatment of nonsmall cell lung cancer, malignant melanoma, and soft tissue sarcoma; and STA-5312, a small-molecule anticancer agent for the treatment of chemotherapy-resistant cancers, which is in two Phase 1 trials for the treatment of solid-tumor cancers and cancers of the blood. The company, formerly known as Neutra Pharmaceuticals Corp., was incorporated in 2000 and is based in Lexington, Massachusetts.